There is not enough well-gathered evidence for policymakers in the USA to make fully informed decisions about the merits of managed care plans and indemnity plans, according to Robert Miller and Harold Luft of the University of California, San Francisco, writing recently in the Journal of the American Medical Association.
The writers conducted a literature analysis to compare health care utilization, quality of care and patient satisfaction of enrollees in managed care and indemnity (fee-for-service) plans. However, they said that "although existing literature provides useful results, policymakers clearly need much more evidence on managed care plan performance if they are to make evidence-based decisions about the future of the health care system."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze